Overview

Update
Total Equity Funding
$25.89M in 4 Rounds from 9 Investors
Most Recent Funding
$5.89M Venture on May 18, 2009
Headquarters:
San Francisco, CA
Description:
Osprey Pharmaceuticals USA develops novel protein therapeutics for the treatment of inflammatory and immune diseases.
Categories:
Pharmaceutical, Biotechnology, Medical
Website:
http://www.ospreypharma.com

Company Details

Update

Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.

The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.

The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.

Funding Rounds (4) - $25.89M

Update
DateAmount / RoundValuationLead InvestorInvestors
May, 2009$5.89M / Venture0
May, 2009undisclosed amount / Series A0
Sep, 2008$11M / Series A6
Jan, 2007$9M / Venture5

Current Team (1)

Update

Board Members and Advisors (2)

Update

Offices/Locations (1)

Update
  • Office

    San Francisco, CA

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos